Home Cart Sign in  
Chemical Structure| 29331-92-8 Chemical Structure| 29331-92-8

Structure of Licarbazepine
CAS No.: 29331-92-8

Chemical Structure| 29331-92-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Licarbazepine, also known as BIA-2-005; GP-47779; LIC-477; LIC-477D; TRI-477, is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects that is related to oxcarbazepine. It is an active metabolite of oxcarbazepine. In addition, an isomer of licarbazepine, eslicarbazepine ((S)-(+)-licarbazepine), is an active metabolite of eslicarbazepine acetate. Oxcarbazepine and eslicarbazepine acetate are inactive on their own, and behave instead as prodrugs to licarbazepine and eslicarbazepine, respectively, to produce their therapeutic effects.

Synonyms: BIA 2-005; GP 47779; TRI-477

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Licarbazepine

CAS No. :29331-92-8
Formula : C15H14N2O2
M.W : 254.28
SMILES Code : O=C(N1C2=CC=CC=C2CC(O)C3=CC=CC=C31)N
Synonyms :
BIA 2-005; GP 47779; TRI-477
MDL No. :MFCD00871817
InChI Key :BMPDWHIDQYTSHX-UHFFFAOYSA-N
Pubchem ID :114709

Safety of Licarbazepine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00099229 Bipolar Disorder PHASE3 COMPLETED 2025-08-06 Investigational Site, Little R... More >>ock, Arkansas, 72211, United States|Investigational Site, Cerritos, California, 90703, United States|Investigational Site, San Diego, California, 92126, United States|Investigational Site, Port Charlotte, Florida, 33952, United States|Investigational Site, Indianapolis, Indiana, 46222, United States|Investigational Site, Newton, Kansas, 67114, United States|Investigational Site, Las Vegas, Nevada, 89103, United States|Investigational Site, Raleigh, North Carolina, 27609, United States|Investigational Site, Cincinnati, Ohio, 45267, United States|Investigational Site, Oklahoma City, Oklahoma, 73118, United States|Investigational Site, Philadelphia, Pennsylvania, 19124, United States|Investigational Site, Austin, Texas, 78756, United States|Investigational Site, Bellaire, Texas, 77401, United States|Investigational Site, Houston, Texas, 77007, United States|Investigational Site, Houston, Texas, 77021, United States|Investigational Site, Kirkland, Washington, 98033, United States|Investigational Site, Dijon, 21033, France|Investigational Site, Strasbourg, 67091, France|Investigational Site, Moscow, 107076, Russian Federation|Investigational Site, Moscow, 113152, Russian Federation|Investigational Site, Moscow, 123367, Russian Federation|Investigational Site, St. Petersburg, 193019, Russian Federation Less <<
NCT00107939 Bipolar Disorder PHASE3 COMPLETED 2025-04-07 Investigational Site, Little R... More >>ock, Arkansas, 72201, United States|Investigational Site, Orange, California, 92868, United States|Investigational Site, Pico Rivera, California, 90660, United States|Investigational Site, San Diego, California, 92108, United States|Investigational Site, San Diego, California, 92126, United States|Investigational Site, Boca Raton, Florida, 33432, United States|Investigational Site, Atlanta, Georgia, 30308, United States|Investigational Site, Chicago, Illinois, 60640, United States|Investigational Site, Joliet, Illinois, 60435, United States|Investigational Site, Indianapolis, Indiana, 46222, United States|Investigational Site, Topeka, Kansas, 66606, United States|Investigational Site, Kansas City, Missouri, 64133, United States|Investigational Site, St. Louis, Missouri, 63104, United States|Invetigational Site, Brooklyne, New York, 11201, United States|Investigational Site, Cedarhurst, New York, 11516, United States|Investigational Site, New York, New York, 10003, United States|Investigational Site, Cincinnati, Ohio, 45267, United States|Investigational Site, Columbus, Ohio, 43210, United States|Investigational Site, Providence, Rhode Island, 02903, United States|Investigational Site, Bellaire, Texas, 77401, United States|Investigational Site, Bellevue, Washington, 98004, United States|Investigational Site, West Allis, Wisconsin, 53227, United States Less <<
NCT00424671 Healthy PHASE1 COMPLETED - Novartis Investigative site, P... More >>rague, Czech Republic Less <<
NCT00238485 Bipolar I Disorder PHASE3 COMPLETED 2025-07-07 -
NCT00228059 Bipolar I Disorder PHASE3 COMPLETED 2025-07-07 Investigational Site, Cerritos... More >>, California, United States Less <<
NCT00426036 Healthy PHASE1 COMPLETED - Novartis Investigative site, P... More >>rague, Czech Republic Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.93mL

0.79mL

0.39mL

19.66mL

3.93mL

1.97mL

39.33mL

7.87mL

3.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories